Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

MS Research Roundup: July 18, 2014
ACTRIMS-ECTRIMS 2014 -- Day 3, afternoon
Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.
Viral triggers of multiple sclerosis.
XVI European Charcot Foundation lecture: nutrition and environment, can MS be prevented?
Episode 37 with Dr. Jeanne Loring on human pluripotent stem cells in a mouse model of MS
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
[Recommendations for a brief international cognitive assessment for multiple sclerosis].
Episode 42 with Dr. Lawrence Steinman on amyloid in experimental autoimmune encephalomyelitis
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
Positive results from Phase 3 CONFIRM clinical trial show efficacy and safety of oral BG-12 in multiple sclerosis
EMD Serono Joins ACP to Launch OPT-UP Study
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.
Scientists probe strategies to repair neuron damage in multiple sclerosis.
Episode 59 with Dr. Helmut Butzkueven on the new MS Brain Health initiative
ACTRIMS-ECTRIMS 2014 -- Day 2, afternoon
Episode 49 with Dr. Hugh Rosen on sphingosine 1-phosphate receptor modulators
SMC Says Yes to Aubagio® (teriflunomide), a New Once Daily First-line Oral Treatment Available for People with an Active Relapsing Remitting Form of MS
Episode 61 with Dr. Yanming Wang on molecular imaging of the myelin sheathing of axons
American Society for Neurochemistry 46th Annual Meeting
Gender as risk factor for autoimmune diseases.
Improving the translational hit of experimental treatments in multiple sclerosis.
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis

Pages